Meghan Sise, MD
Enriched profileDirector of Onconephrology, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School · Massachusetts General Hospital
Meghan Sise is Director of Onconephrology, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School at Massachusetts General Hospital. OpenAlex indexes 272 publications with 9,785 citations (h-index 46); ClinicalTrials.gov lists 2 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Meghan Sise, MD, is Director of Onconephrology, Massachusetts General Hospital. The public record shows 272 publications with 9,785 citations (h-index 46), centered on Hepatitis C virus research, Cancer Immunotherapy and Biomarkers, Acute Kidney Injury Research. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 8 companies, 4 NIH-funded awards (2018–2026).
- Most recent indexed publication: 2025 · bioRxiv
- Top research focus: Hepatitis C virus research
- 2 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 17 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 122.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:
- Infliximab for Immune Checkpoint Inhibitor Associated AKI
Sponsor: Massachusetts General Hospital
- Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease
Sponsor: Angion Biomedica Corp
Industry payments
Updated 27 Aug 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Otsuka Pharmaceutical Development & Commercialization, Inc.Program year20257 payments$15,513openpaymentsdata.cms.gov ↗
- Vertex Pharmaceuticals IncorporatedProgram year20252 payments
- Travere Therapeutics, Inc.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
75.5%Loop diuretic28.3%Torsemide70%Furosemide30%Part D<11 patientsCalcium channel blocker20.7%Amlodipine Besylate100%Part D≥22 patientsMetabolism & gastrointestinal
18.1%H2 blocker12.7%Famotidine100%Part D<11 patientsSGLT2 inhibitor5.5%Farxiga100%Part D<11 patientsGenitourinary & hormones
6.3%alpha-Adrenergic Blocker6.3%Tamsulosin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
4 NIH research awards on record, funded 2018–2026 per NIH RePORTER. The latest:
- Rapid Diagnosis and Treatment Response Phenotyping of Immune Checkpoint Inhibitor-Associated Acute Interstitial Nephritis
Yale University
FY2026$1,407,724R01DK140717 - Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer
Massachusetts General Hospital
FY2026$647,716R01DK130839 - Pilot Randomized Clinical Trial of Glucocorticoid-Sparing Immunosuppressive Treatments for Immune Checkpoint Inhibitor-Associated AKI
Massachusetts General Hospital
FY2026$312,324R01DK144161
Congress activity
Updated 27 Aug 2026
9 congress contributions (2018–2025) across ASCO, ASH per OpenAlex. The most recent:
- Detection of immune-related adverse events among hospitalized patients using large language models.
ASCO Annual Meeting
ASCO2024Co-author - Isatuximab for Treatment of Monoclonal Gammopathy of Renal Significance (MGRS) - Results from a Prospective Phase 2 Trial
ASH Annual Meeting
ASH2024Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Large Discordance between Creatinine-Based and Cystatin C-Based eGFRs is Associated with Falls, Hospitalizations, and Death in Older Adults.
Clinical journal of the American Society of Nephrology
Article2024 - AKI treated with kidney replacement therapy in critically Ill allogeneic hematopoietic stem cell transplant recipients.
Bone marrow transplantation
Article2024
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/reachmd_nephrology-fsgs-cme-activity-7382176791139942401-EUfk
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Columbia University College of Physicians & Surgeons
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →massgeneral.org ↗ - MS
Patient-Oriented Research, Columbia University Mailman School of Public Health
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onconephrology.mgh.harvard.edu ↗ - BS
University of Notre Dame, summa cum laude
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onconephrology.mgh.harvard.edu ↗ - Board Certified
Internal Medicine (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →massgeneral.org ↗ - Residency
Internal Medicine, Massachusetts General Hospital
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onconephrology.mgh.harvard.edu ↗ - Fellowship
Nephrology, Columbia University Medical Center / New York Presbyterian Hospital
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onconephrology.mgh.harvard.edu ↗ - Research Fellowship
Nephrology, Massachusetts General Hospital (under Ravi Thadhani and Raymond Chung)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onconephrology.mgh.harvard.edu ↗
Editorial & leadership roles
journal and society appointments- Associate Editor
NEJM Clinician (New England Journal of Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clinician.nejm.org ↗
Awards & honors
honors on the public record- Janeway Prize (highest achievement/abilities at graduation)
Columbia University College of Physicians & Surgeons
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onconephrology.mgh.harvard.edu ↗ - Claflin Distinguished Scholar Award
Massachusetts General Hospital
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onconephrology.mgh.harvard.edu ↗
Secondary affiliations
appointments beyond the home institution- Principal Investigator
MGH Onconephrology research program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onconephrology.mgh.harvard.edu ↗
Media & interviews
press, podcasts and appearances- Contributor
Mass General Advances in Motion (multiple feature articles on AKI/CAR-T therapy, COVID-19 and nephrology, Medical Grand Rounds)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →advances.massgeneral.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
James Januzzi, MD
Massachusetts General Hospital
Maurizio Fava, MD
Massachusetts General Hospital
Steven Greenberg, MD
Massachusetts General Hospital
David Scadden, MD
Massachusetts General Hospital